ResMed operates in a structurally underdiagnosed market where demand is driven by medical necessity rather than economic cycles. Its hardware-led model evolves into a recurring revenue ecosystem supported by patient adherence and provider integration. While GLP-1 concerns may moderate growth at the margin, the long-term demand outlook remains intact. At ~22× P/E, returns are likely to be driven by steady earnings compounding rather than multiple expansion.

Earnings growth is a key driver of long-term stock returns, and cost optimization is often an underappreciated lever. By analyzing earnings transcripts and filings, investors can identify whether management has concrete plans to improve profitability. Going further, mapping these initiatives to COGS, SG&A, or R&D provides a clearer view of margin expansion and earnings quality — turning qualitative insights into a real modelling edge.

Most investors focus on what stocks to buy, but far fewer consider how much cash to hold. This simple framework uses the S&P 500’s P/E ratio as a guide to adjust cash allocation based on market valuation. When valuations become stretched, holding some cash can provide flexibility to navigate drawdowns and deploy capital when opportunities arise, while still remaining invested for the long term.